Fungal Spine Infections

Fungal spine infections (fungal spondylodiscitis or vertebral osteomyelitis) are rare but serious infections accounting for only 1-2% of all spinal infections. However, incidence is rising due to increasing numbers of immunocompromised patients from HIV, solid organ transplantation, chemotherapy, and chronic immunosuppressive medications.

Routes of Infection

Specific Fungal Pathogens

The risk-factor and poor-prognosis lists name mucormycosis (as a diabetic risk and a bad-prognosis pathogen), but it is never developed - a dangerous omission, because it behaves and is treated very differently from Candida and Aspergillus and is a surgical emergency.

• Agents and hosts. Caused by the Mucorales (Rhizopus, Mucor, Rhizomucor, Lichtheimia, Cunninghamella). The classic host is uncontrolled diabetes, especially diabetic ketoacidosis (acidosis impairs neutrophils and frees iron), plus iron overload / deferoxamine therapy (the drug acts as a siderophore that delivers iron to the fungus), haematological malignancy/neutropenia and transplantation, and - for the spine specifically - IV drug use and direct/traumatic inoculation.
• Why it is different: angioinvasion. Mucorales are angioinvasive - they invade blood vessels causing thrombosis, infarction and rapid, extensive tissue necrosis. Disease spreads fast, and antifungals penetrate the dead, thrombosed tissue poorly - which is why surgery is central, not adjunctive.
• On histology. Broad (wide), non-septate (pauci-septate), ribbon-like hyphae with wide-angle (approximately 90-degree), irregular branching - contrast with Aspergillus (narrow, septate hyphae, acute-angle, approximately 45-degree branching). Cultures are frequently negative, so the diagnosis is often made on histology; do not wait for a culture to act.
• Treatment - and the fatal trap. It is a surgical emergency: urgent, aggressive and often repeated surgical debridement of all necrotic tissue, PLUS liposomal amphotericin B (first-line), with isavuconazole or posaconazole for step-down/salvage. Voriconazole, fluconazole and the echinocandins are INEFFECTIVE against Mucorales - so a patient on voriconazole for presumed Aspergillus who deteriorates may in fact have mucormycosis. Reverse the driver (correct DKA/hyperglycaemia, stop deferoxamine, reduce immunosuppression). Mortality is very high.

The CACAO mnemonic and the routes-of-infection table both flag Actinomyces ("technically bacteria but mimics fungus") but never develop it, and its close mimic Nocardia is not mentioned at all. Both are filamentous, branching Gram-positive bacteria that can be mistaken for fungi - but they are treated with antibiotics, not antifungals, so recognising them changes management completely.

• Actinomyces (e.g. A. israelii). An anaerobic/microaerophilic branching Gram-positive filament that is endogenous flora (oropharynx, GI tract, female genital tract). It reaches the spine by contiguous spread - classically cervicofacial ("lumpy jaw") extending to the cervical spine, or thoracic (aspiration) and abdominopelvic (IUD-associated) disease invading adjacent vertebrae. It crosses tissue planes and the disc, forms chronic indurated masses with sinus tracts discharging "sulfur granules", and is NOT acid-fast. Treatment is prolonged high-dose penicillin (IV then oral, often 6-12 months) - not antifungals.
• Nocardia (e.g. N. asteroides complex). An aerobic branching Gram-positive filament that is weakly/partially acid-fast (modified Ziehl-Neelsen / Kinyoun) - the key feature separating it from Actinomyces. It is environmental (soil), affects the immunocompromised (steroids, transplant, malignancy), and typically causes primary pulmonary disease with haematogenous dissemination to brain and bone/spine. Treatment is high-dose co-trimoxazole (TMP-SMX), often with a carbapenem or amikacin for severe disease, and is prolonged.
• Why this matters here. When a "fungal-looking" granulomatous spine infection is actually Actinomyces or Nocardia, the cure is antibiotics. The practical safeguard is to send the biopsy for bacterial (aerobic AND anaerobic), fungal and mycobacterial culture with the right stains (Gram, modified acid-fast) and to avoid anchoring on an "antifungal" plan.

Clinical Features

Algorithm

View larger

Treatment Algorithm

Global Epidemiology

Fungal spine infection accounts for roughly 1-2% of all spinal infections worldwide, with a reported incidence near 2.2 per 100,000 person-years. Distribution is driven by host immunosuppression (HIV, transplantation, haematological malignancy, chronic steroids, diabetes) and by geography for the endemic mycoses. Candida and Aspergillus occur worldwide and are largely healthcare- or immunosuppression-associated, whereas Coccidioides (Southwest USA, parts of Central/South America), Histoplasma (Americas, parts of Africa/Asia) and Blastomyces (North America) are geographically restricted. In published pooled series the lumbar spine is most often affected, with male predominance and a mean age in the mid-50s.

Side-by-Side Guidance

Registries and Practice Variation

There is no dedicated arthroplasty-style registry for spinal fungal infection; evidence rests on pooled case series and surveillance networks (e.g. ECMM/FungiScope, national antifungal-resistance surveillance such as CDC/EUCAST programmes). High-resource settings emphasise molecular diagnostics (PCR, MALDI-TOF), beta-D-glucan/galactomannan assays, therapeutic drug monitoring of azoles, and ready access to liposomal amphotericin B and newer triazoles. In limited-resource settings, delayed diagnosis, restricted access to voriconazole/isavuconazole and amphotericin formulations, and overlap with tuberculosis (which is far more common and radiographically similar) drive worse outcomes and a lower threshold for empiric anti-tuberculous therapy before fungal disease is considered.